

CONCORD DRUGS LIMITED

Admn. Office & Factory : Survey No. 249, Brahmanapally Village, Hayathnagar Mandal, R.R.Dist. - 501 511. (T.S) INDIA.
E-mail : concorddrugsltd@gmail.com Website : www.concorddrugs.in

To,

Date:13.08.2022

BSE Limited,
P.J. Towers, Dalal Street,
Mumbai-400001

Dear Sir/Madam,

Sub: Outcome of board meeting held on 13.08.2022

Ref: Company's letter dated 27.07.2022

With reference to the subject cited, this is to inform the Exchange that at the meeting of the Board of Directors of Concord Drugs Limited held on Saturday, 13.08.2022 at 3:00 p.m. at the registered office of the company at Survey No. 249, Brahmanapally Village, Hayathnagar Mandal-501511 Telangana, the following were considered and approved:

1. Un-audited financial results for the quarter ended 30.06.2022. **(Enclosed)**
2. Limited Review Report as per Regulation 33 of SEBI (LO&DR) Regulations, 2015 for the Quarter ended 30.06.2022. **(Enclosed)**

This is for the information and records of the Exchange, please.


The meeting concluded at 4.30 p.m.

Thanking you.

Yours sincerely,
For Concord Drugs Limited

S. N. Reddy

S. Nagi Reddy
Chairman & Managing Director
DIN: 01764665





CONCORD DRUGS LIMITED


Admn. Office & Factory : Survey No. 249, Brahmanapally Village, Hayathnagar Mandal, R.R.Dist. - 501 511. (T.S) INDIA.
E-mail : concorddrugsLtd@gmail.com Website : www.concorddrugs.in

STATEMENT OF UN AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2022

Particulars	Quarterly ended			Year ended
	30-Jun-22 (Un Audited)	31-Mar-22 (Audited)	30-Jun-21 (Un Audited)	31-Mar-22 (Audited)
I Revenue from Operations				
a. Net sales from Operations	1,253.148	1,546.46	2,021.95	5,895.65
b. Other Operating Income	0.603	2.36	2.152	10.08
II Other Income				
III Total Revenue (I+II)	1,253.75	1,548.82	2,024.10	5,905.73
IV Expenses				
a. Cost of Material Consumed	869.109	1,065.71	1,566.490	4,441.15
b. Changes in Inventories of finished goods, work-in-progress and stock-in-trade	107.611	-193.07	18.480	231.06
c. Employees Benefit Expenses	116.168	160.10	104.880	489.10
d. Finance Costs	33.829	23.45	95.760	168.07
e. Depreciation and Amortisation expense	38.879	37.10	53.160	176.45
f. Other expenses	62.830	447.99	105.300	637.21
Total Expenses	1,228.42	1,541.29	1,944.07	5,680.92
V Profit/ (Loss) before Exceptional item and tax (III-IV)	25.33	7.53	80.03	224.81
VI Exceptional Items	-	-	-	-
VII Profit/ (Loss) before tax (V-VI)	25.326	7.531	80.032	224.805
VIII Tax Expense:				
a. Current tax	6.585	4.80	11.26	65.37
b. Deferred tax charge/credit	6.632	5.14	24.68	67.12
	-0.047	-0.34	13.42	1.75
IX Profit/ (Loss) for the period (VII-VIII)	18.74	2.73	68.77	159.43
X Other Comprehensive Income				
Items that will not be reclassified to profit or loss	-	-	-	-
Total Comprehensive Income for the period (comprising profit and other comprehensive income for the period) (IX+X)	18.74	2.73	68.771	159.43
XI Paid-up equity share capital (Face value of the share- Rs. 10 each)	874.38	874.38	874.38	874.38
Other Equity	1,980.43	1,961.68	1,871.020	1,961.68
XII Earnings per share (of Rs. 10 each)				
XIII a. Basic (in Rs)	0.21	0.03	0.79	1.82
b. Diluted (in Rs)	0.21	0.03	0.79	1.82

Notes:

- The financial results of the company have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under section 133 of the Companies Act, 2013, read with the relevant rules issued there under.
- The above standalone financial results as reviewed by the audit committee have been approved by Board of Directors at its meeting held on 13th Aug, 2022
- Figures of the corresponding previous periods are regrouped and reclassified wherever considered necessary to correspond with current period's presentation.
- The results are also available on the website of the Company www.concorddrugs.in



By Order of the Board
For Concord Drugs Limited

S. Nagi Reddy
Managing Director
DIN: 01764665

Place: Hyderabad
Date: 13th Aug, 2022



PUNDARIKASHYAM AND ASSOCIATES

CHARTERED ACCOUNTANTS

D.No. 3-6-666, 3rd Floor, Barwale Chambers, Street No.11, Himayat Nagar,
Hyderabad - 500 029, Cell : 9440464339, Ph : 040 - 40072693,

E-mail : info@pkas.in / infoong@pkas.in

GSTIN : 36AAJFP6218J1ZY

Branches : 1. Door No. 76-14-243/1A, Vasavi Kalyana Mandapam Road, Sivalayam Centre, Bhavani Puram, Vijayawada - 12.
2. 7-310, Shop No. 204, Padma Towers, South Bypass Road, Ongole, 523001.

Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)


To the Board of Directors of Concord Drugs Limited,

1. We have reviewed the accompanying statement of standalone unaudited financial results ('the Statement') of Concord Drugs Limited ('the company') for the quarter ended 30 June 2022, being submitted by the Company pursuant to the requirements of the regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time.
2. The statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the act'), SEBI circular CIR/CFD/FAC/62/2016, dated 5 July 2016, (hereinafter referred to as 'the SEBI Circular'), and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Act, the SEBI Circular, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Pundarikashyam and Associates
Chartered Accountants
FRN: 011330S.

B. Surya  *Rao*

B.Surya Prakasa Rao
(Partner)
MNo: 205125
UDIN No: 22205125AOYXCN5585

Place: Hyderabad
Date: 13-08-2022